<DOC>
	<DOCNO>NCT01336842</DOCNO>
	<brief_summary>The purpose study find panobinostat take cisplatin pemetrexed use safely without increase side effect combination well effect platinum-based doublet chemotherapy alone .</brief_summary>
	<brief_title>Study Cisplatin Pemetrexed Combination With Panobinostat Solid Tumors</brief_title>
	<detailed_description>The purpose phase I study oral panobinostat plus cisplatin pemetrexed determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLTs ) patient advance solid tumor , emphasis non-small cell lung cancer . Another purpose study find oral panobinostat combination cisplatin pemetrexed administer safely without significant increase toxicity combination increase efficacy compare platinum-based doublet chemotherapy alone .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological cytological proven advance solid tumor curative standard treatment available . Must measurable evaluable disease . Male female patient age ≥ 18 year old . Any number prior chemotherapy regimen . ECOG Performance Status ≤ 2 life expectancy great 3 month . Clinically euthyroid ( may thyroid hormone replacement ) Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day first administration study treatment . Ability provide write informed consent Must meet follow laboratory criterion : Hematology : Neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9 g/dL Biochemistry : AST/SGOT ALT/SGPT ≤ 2.5 x upper limit normal ( ULN ) ≤ 5.0 x ULN transaminase elevation due disease involvement Serum bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN 24hour creatinine clearance ≥ 50 ml/min Total serum calcium ( correct serum albumin ) ionize calcium ≥ LLN ≤ ULN Serum potassium ≥ LLN ≤ ULN Serum sodium ≥ LLN ≤ ULN Serum albumin ≥ LLN 3g/dl Serum magnesium ≥ LLN ≤ ULN Any elevate Alkaline Phosphatase due bone metastasis enrol Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer . Patients need valproic acid medical condition study within 5 day prior first panobinostat treatment . Patients receive chemotherapy , investigational drug undergone major surgery &lt; 4 week prior start study drug recover side effect therapy . Impaired cardiac function Other concurrent severe and/or uncontrolled medical condition could cause unacceptable safety risk compromise compliance protocol Concomitant use drug generally recognize risk cause torsades de pointes treatment discontinue switched different medication prior start study drug Patients unresolved diarrhea ≥ CTCAE grade 2 Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral panobinostat . Inability swallow panobinostat capsule whole . Concomitant use anticancer therapy radiation therapy Uncontrolled symptomatic brain metastasis . Women pregnant breast feed woman childbearing potential ( WOCBP ) willing use double barrier method contraception study 3 month end treatment . One method contraception must barrier method . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Male patient whose sexual partner WOCBP use double method contraception study 3 month end treatment . Known positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require Any significant history noncompliance medical regimen inability grant reliable informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>panobinostat</keyword>
	<keyword>cisplatin</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>dose escalation</keyword>
</DOC>